November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
PD-1 Inhibitor Misses Primary OS Endpoint in Phase III Trial for Metastatic TNBC
May 21st 2019Pembrolizumab monotherapy missed the prespecified primary endpoint of superior overall survival compared to chemotherapy in the phase III KEYNOTE-119 trial, in which the PD-1 inhibitor was being investigated as a second- or third-line treatment for patients with metastatic triple-negative breast cancer.
Read More
Study Shows Risk of Death From Breast Cancer May Be Reduced With Low-Fat Diet
May 16th 2019By eating a balanced, low-fat diet and daily portions of vegetables, fruit, and grains, women have a 21% lower risk of dying from breast cancer, according to research to be presented during the upcoming 2019 ASCO Annual Meeting in Chicago.
Read More
Immunotherapy Potential in Breast Cancer Draws Excitement
May 13th 2019Findings from ongoing immunotherapy studies are expected to change the treatment paradigm in breast cancer as these agents become available to larger subsets of patients, according to Hope S. Rugo, MD, and Elizabeth A. Mittendorf, MD, PhD, who presented data at the 36th Annual Miami Breast Cancer Conference® hosted by Physicians’ Education Resource®, LLC.
Read More
[Fam-] Trastuzumab Deruxtecan Demonstrates Encouraging Responses in Advanced HER2+ Breast Cancer
May 9th 2019In topline findings from the phase II DESTINY-BreastO1 study, [fam-] trastuzumab deruxtecan demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine.
Read More
Adjuvant T-DM1 Approved by FDA for HER2+ Early Breast Cancer
May 4th 2019Ado-trastuzumab emtansine has been approved by the FDA for use as an adjuvant treatment option for patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab and chemotherapy.
Read More
New Companion Diagnostic Test Launched for Patients With Breast, Gastric Cancers
April 30th 2019A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has been launched by Roche to help identify <em>HER2</em> amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.
Read More
This article focuses specifically on the role of ovarian suppression in young premenopausal women. It reviews methods of ovarian suppression, provides evidence from recent pivotal clinical trials, outlines guidelines for its use, and discusses best practices and practical management applications.
Read More